Submit Deal

Announced

2 Jun 2022

Completed

2 Jun 2022

AstraZeneca, CR Capital Magament and Panlin capital led a $50m Series B round in NuProbe.

Synopsis

AstraZeneca, CR Capital Magament and Panlin capital led a $50m Series B round in NuProbe, a biotechnology company, with participation from Gaorong Capital, Deguan Capital, Pappas Capital, BioTrack Capital, Sequoia, Yonghua Capital and Tuobang Capital.

Principals

target

NUPROBE

bidder

Astrazeneca

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (2)

yingshuang chai

CEO and Chairman at NUPROBE

Manager

target

Deal

£ 40 M

Total Value

yan chen

Associate at Junhe

Lawyer

target

Deal

£ 40 M

Total Value

Bidder Team (5)

aradhana sarin

CFO at ASTRAZENECA PLC

Manager

bidder

Deals

£ 7.45 B

Total Value

pascal soriot

CEO at ASTRAZENECA PLC

Manager

bidder

Deals

£ 43.78 B

Total Value

neil shen

Founding Partner at HONGSHAN (EX-SEQUOIA CAPITAL CHINA)

Investor

bidder

Deals

£ 15.88 B

Total Value

art pappas

CEO & Managing General Partner at PAPPAS CAPITAL

Investor

bidder

Deal

£ 40 M

Total Value

feng tao

Co-Founder & Partner at BIOTRACK CAPITAL

Investor

bidder

Deal

£ 40 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy